30 closest matches · ranked by relevance
Oncology Patients Receiving Chemotherapy
Primary: Number of Hypersensitivity Reactions to Treatment With an Anti-CD20 Antibody or Paclitaxel — 2; 3 Participants
Inflammatory Bowel Diseases
Primary: Number of Participants With Acute Infusion Reaction as Assessed by the Nursing Staff of the Infusion Unit — 27; 30; 0; 0 Participants
Rheumatoid Arthritis
Primary: Percentage of Participants With an Infusion Reaction Within 24 Hours After Infusion — 29.7; 17.9 percentage of participants — p=0.238
Multiple Sclerosis
Primary: Incidence of Infusion Related Reactions With Rapid Infusion Will be Reported — 0; 0 infusion reactions
Alpha1-antitrypsin Deficiency · Healthy Volunteers
Primary: Number of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event (Regardless of Adverse Event Causality…
Purpura, Thrombocytopenic, Idiopathic
Primary: Free Hemoglobin — 13.057; 12.371 g/dL
Infusion Reaction · Monoclonal Antibody
Primary: Number of Participants With Standard Infusion Reactions (SIR) at Cycle 1 and During Subsequent Cycles of Monoclonal Antibody Infusion — 14; 26; 4; 35 Participants
Iron Deficiency Anemia
Primary: Efficacy of 1020 mg of Ferumoxytol Over 15 Minutes. Hemoglobin Measurements Will Take Place at Four and Eight Week Visit. — 85; 58; 92; 86 percentage of participants
Hematologic Diseases · Secondary Immune Deficiency
Primary: Infusion Time of Multigam IV 5% and Multigam IV 10% — 4.92; 2.29 hour — p=<0.0001
Type 1 Diabetes Mellitus
Primary: Visual Analog Scale (VAS) Pain Score in the Abdominal, Arm, Thigh, and Buttock Areas — 3.4; 2.0; 1.8; 1.9 millimeter
Indolent or Intermediate Grade B-cell Malignancy
Primary: Incidence of Grade III and IV Hypersensitivity Reactions — 0 percentage of patients
Multiple Sclerosis · Infusion Reaction
Primary: Proportion of Participants With Infusion-related Reaction (IRR) on Day 0 — 5; 6 participnats
Refractory Chronic Gout
Primary: Number of Participants With Infusion Reactions — 42 Participants
Cutaneous Squamous Cell Carcinoma · Basal Cell Carcinoma
Primary: Rate of Adverse Events — 0; 0; 5 Participants
Primary Immunodeficiency Disease
Primary: Percentage of Participants Who Experienced at Least 1 Adverse Event Causally Related to the Administration of the Study Drug — 19.0 Percentage of participants
Anatomic Stage 0 Breast Cancer AJCC v8 · Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage IA Breast Cancer AJCC v8
Primary: Proportion of Patients With Grade 2 or Greater Reactions That Require Parenteral Rescue Medications to Treat an Infusion Hypersensitivity Reaction (HSR) After the First…
Anaerobic Infection · Infectious Enterocolitis · Amebic Dysentery
Primary: Number of Participants With Adverse Drug Reaction (ADR) — 7; 1 Participants
Acute Anterior Myocardial Infarction
Primary: Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion — 15.1; 17.9; 17.2 Percentage of Left…
Late Complication From Kidney Transplant
Primary: Change in Inflammation on Renal Allograft Biopsy From Baseline to 6 Months — 3; 10 Participants — p=0.033
Advanced Malignant Neoplasm
Primary: Time-to-carboplatin or Oxaliplatin Acute Hypersensitivity Reaction — 4.4; NA months — p=0.90
Lymphoma
Primary: Incidence of Infections Which Requires Procedures, Medication or Hospitalization — 0.16; 0.27; 0.16; 0.26 events of infection per person-year
Rheumatoid Arthritis
Primary: Number of Participants With Adverse Drug Reactions (ADRs) — 3; 1 Participants
Primary Immunodeficiency
Primary: Percentage of Responders — 86.7; 73.3; 73.3; 77.8 percentage of responders
Pain · Fever
Primary: To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting. — 0; 0…
Kawasaki Disease
Primary: The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion — 11; 11…
Complex Regional Pain Syndrome
Primary: Number of Participants With Occurrence of Any Treatment Emergent Adverse Event (TEAE) — 277; 27; 275; 267 Participants
Dehydration
Primary: Technical Challenges — 2; 3; 2; 2 participants
End Stage Renal Disease · Chronic Kidney Diseases
Primary: Need for Dialysis in the First 30 Days Post-transplant — 10; 10 Participants
Relapsing-remitting Multiple Sclerosis
Primary: Percentage of the Sites Developing a Injection Site Reaction (ISR) Reported by Participants 24 Hours After Each Injection — 31; 37 Percentage of sites
Relapsing Multiple Sclerosis
Primary: Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu-like Symptom Score — 8.5; 9.1 MSTCQ score (units on a scale)